GRI Bio regains compliance with Nasdaq continued listing standards

GRI Bio, Inc.

Received Nasdaq notice on July 2, 2024 curing equity deficiency under Listing Rule 5550(b).
Scheduled hearing before Nasdaq Hearings Panel has been canceled.
Now in compliance with all applicable continued listing standards on Nasdaq Capital Market.
No financial impact or operational changes disclosed; CEO expresses focus on core business.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.